Dicerna pushed up price and contacted other suitors before making deal with Novo Nordisk

Novo Nordisk wasn't alone in expressing interest in acquiring biotech business Dicerna, but after a bidding war, the Danish pharmaceutical company's offer was the most economically attractive, documents reveal.

Photo: Valdemar Ren

When the hammer came down, Novo Nordisk's final bid for US-based Dicerna far exceeded its initial offer.

This is evident in documents publicized Wednesday evening, revealing the internal negotiations between the two companies, which also involved other would-be suitors.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs